ARF5

Summary

ARF5 (ARF GTPase 5, HGNC:658) is a protein-coding gene on chromosome 7q32.1, encoding ADP-ribosylation factor 5 (P84085). GTP-binding protein involved in protein trafficking; may modulate vesicle budding and uncoating within the Golgi apparatus.

This gene is a member of the human ADP-ribosylation factor (ARF) gene family. These genes encode small guanine nucleotide-binding proteins that stimulate the ADP-ribosyltransferase activity of cholera toxin and play a role in vesicular trafficking and as activators of phospholipase D. The gene products include 6 ARF proteins and 11 ARF-like proteins and constitute 1 family of the RAS superfamily. The ARF proteins are categorized as class I (ARF1, ARF2,and ARF3), class II (ARF4 and ARF5) and class III (ARF6). The members of each class share a common gene organization.

Source: NCBI Gene 381 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 25 total — 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_001662

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:658
Approved symbol	ARF5
Name	ARF GTPase 5
Location	7q32.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000004059
Ensembl biotype	protein_coding
OMIM	103188
Entrez	381

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000000233, ENST00000415666, ENST00000459680, ENST00000463733, ENST00000467281, ENST00000489673, ENST00000864451, ENST00000864452, ENST00000934467, ENST00000934468

RefSeq mRNA: 1 — MANE Select: NM_001662 NM_001662

CCDS: CCDS34745

Canonical transcript exons

ENST00000000233 — 6 exons

Exon	Start	End
ENSE00000882271	127591213	127591700
ENSE00001872691	127588411	127588565
ENSE00003494180	127589083	127589163
ENSE00003504066	127589485	127589594
ENSE00003676786	127590963	127591088
ENSE00003678978	127590066	127590137

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 99.01.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 98.1124 / max 541.3539, expressed in 1828 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
80890	98.1124	1828

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.01	gold quality
prefrontal cortex	UBERON:0000451	98.92	gold quality
frontal cortex	UBERON:0001870	98.88	gold quality
Brodmann (1909) area 9	UBERON:0013540	98.87	gold quality
skin of leg	UBERON:0001511	98.84	gold quality
right frontal lobe	UBERON:0002810	98.82	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	98.81	gold quality
zone of skin	UBERON:0000014	98.79	gold quality
skin of abdomen	UBERON:0001416	98.77	gold quality
body of pancreas	UBERON:0001150	98.75	gold quality
esophagus mucosa	UBERON:0002469	98.73	gold quality
cerebral cortex	UBERON:0000956	98.69	gold quality
granulocyte	CL:0000094	98.68	gold quality
primary visual cortex	UBERON:0002436	98.68	gold quality
superior frontal gyrus	UBERON:0002661	98.68	gold quality
right hemisphere of cerebellum	UBERON:0014890	98.68	gold quality
cerebellar hemisphere	UBERON:0002245	98.63	gold quality
cerebellum	UBERON:0002037	98.62	gold quality
cerebellar cortex	UBERON:0002129	98.62	gold quality
nucleus accumbens	UBERON:0001882	98.56	gold quality
anterior cingulate cortex	UBERON:0009835	98.52	gold quality
mucosa of transverse colon	UBERON:0004991	98.51	gold quality
cortical plate	UBERON:0005343	98.49	gold quality
putamen	UBERON:0001874	98.48	gold quality
monocyte	CL:0000576	98.46	gold quality
leukocyte	CL:0000738	98.46	gold quality
caudate nucleus	UBERON:0001873	98.44	gold quality
right uterine tube	UBERON:0001302	98.39	gold quality
pancreas	UBERON:0001264	98.35	gold quality
esophagus	UBERON:0001043	98.27	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-8271	no	519.03
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting ARF5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-556-3P	99.74	68.75	1203
HSA-MIR-1825	99.72	68.11	1089
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-4687-5P	99.14	66.26	488
HSA-MIR-6889-3P	98.84	67.35	1198
HSA-MIR-6529-3P	98.68	66.76	1020

Literature-anchored findings (GeneRIF, showing 8)

• a crucial role for class II Arf proteins (Arf4 and Arf5) in the dengue flavivirus life cycle (PMID:22105072)
• The lipid droplets deposition and the cellular triacylglycerol content are significantly increased by siRNA-mediated depletion of Arf5. (PMID:22185782)
• A protein encoded by this locus was found to be differentially expressed in postmortem brains from patients with atypical frontotemporal lobar degeneration. (PMID:22360420)
• a novel molecular mechanism of circular dorsal ruffles ring size control through the ARAP1-Arf1/5 pathway. (PMID:22573888)
• BRAG2 acts at clathrin-coated pits to promote integrin internalization by activating Arf5 and suggest a previously unrecognized role for Arf5 in clathrin-mediated endocytosis of specific cargoes. (PMID:22815487)
• GORAB missense mutation disrupt ARF5 binding in Golgi apparatus in patients, with genetic skin diseases. (PMID:26000619)
• ARF5 and Rab1b exhibit RNA-binding capacity, suggesting a role for domain 3 of the IRES in RNA localization into specific cellular compartments. (PMID:30655362)
• An Arf/Rab cascade controls the growth and invasiveness of glioblastoma. (PMID:33443570)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	arf5	ENSDARG00000070472
danio_rerio	ARF5	ENSDARG00000113899
mus_musculus	Arf5	ENSMUSG00000020440
drosophila_melanogaster	Arf4	FBGN0013749
caenorhabditis_elegans		WBGENE00000183

Paralogs (30): SAR1A (ENSG00000079332), ARFRP1 (ENSG00000101246), TRIM23 (ENSG00000113595), ARL6 (ENSG00000113966), ARL1 (ENSG00000120805), ARL4A (ENSG00000122644), ARL8B (ENSG00000134108), ARF3 (ENSG00000134287), ARL3 (ENSG00000138175), ARL5C (ENSG00000141748), ARF1 (ENSG00000143761), ARL8A (ENSG00000143862), ARL11 (ENSG00000152213), SAR1B (ENSG00000152700), ARL5A (ENSG00000162980), ARF6 (ENSG00000165527), ARL5B (ENSG00000165997), ARF4 (ENSG00000168374), ARL13B (ENSG00000169379), ARL13A (ENSG00000174225), ARL10 (ENSG00000175414), ARL4D (ENSG00000175906), ARL14 (ENSG00000179674), ARL15 (ENSG00000185305), ARL17A (ENSG00000185829), ARL4C (ENSG00000188042), ARL9 (ENSG00000196503), ARL2 (ENSG00000213465), ARL16 (ENSG00000214087), ARL17B (ENSG00000228696)

Protein

Protein identifiers

ADP-ribosylation factor 5 — P84085 (reviewed: P84085)

All UniProt accessions (3): P84085, A4D0Z3, C9J1Z8

UniProt curated annotations — full annotation on UniProt →

Function. GTP-binding protein involved in protein trafficking; may modulate vesicle budding and uncoating within the Golgi apparatus. (Microbial infection) Functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase.

Subunit / interactions. Interacts (when activated) with GGA1, GGA2 and GGA3; the interaction is required for proper subcellular location of GGA1, GGA2 and GGA3. Binds ASAP2. Interacts with NCS1/FREQ at the Golgi complex. Interacts with RAB11FIP3 and RAB11FIP4.

Subcellular location. Golgi apparatus. Cytoplasm. Perinuclear region. Membrane. trans-Golgi network membrane.

Similarity. Belongs to the small GTPase superfamily. Arf family.

RefSeq proteins (1): NP_001653* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005225	Small_GTP-bd	Domain
IPR006689	Small_GTPase_ARF/SAR	Family
IPR024156	Small_GTPase_ARF	Family
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR045872	Arf1-5-like	Family

Pfam: PF00025

UniProt features (25 total): helix 9, strand 7, binding site 3, turn 3, initiator methionine 1, chain 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2B6H	X-RAY DIFFRACTION	1.76

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P84085-F1	86.31	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 24–31; 67–71; 126–129

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

11 pathways

ID	Pathway
R-HSA-6807878	COPI-mediated anterograde transport
R-HSA-6811434	COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-199977	ER to Golgi Anterograde Transport
R-HSA-199991	Membrane Trafficking
R-HSA-392499	Metabolism of proteins
R-HSA-446203	Asparagine N-linked glycosylation
R-HSA-5653656	Vesicle-mediated transport
R-HSA-597592	Post-translational protein modification
R-HSA-6811442	Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-8856688	Golgi-to-ER retrograde transport
R-HSA-948021	Transport to the Golgi and subsequent modification

MSigDB gene sets: 154 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, MORF_RAB5A, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, GGGTGGRR_PAX4_03, MORF_PSMC2, MORF_ATOX1, chr7q32, MODULE_86, PID_PI3KCI_PATHWAY, MORF_GPX4, MODULE_226, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, MODULE_98

GO Biological Process (4): intracellular protein transport (GO:0006886), retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum (GO:0006890), vesicle-mediated transport (GO:0016192), protein transport (GO:0015031)

GO Molecular Function (4): GTPase activity (GO:0003924), GTP binding (GO:0005525), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (6): cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
Membrane Trafficking	2
ER to Golgi Anterograde Transport	1
Golgi-to-ER retrograde transport	1
Transport to the Golgi and subsequent modification	1
Vesicle-mediated transport	1
Post-translational protein modification	1
Metabolism of proteins	1
Intra-Golgi and retrograde Golgi-to-ER traffic	1
Asparagine N-linked glycosylation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
intracellular protein localization	2
transport	2
cytoplasm	2
protein transport	1
intracellular transport	1
Golgi vesicle transport	1
cellular process	1
establishment of protein localization	1
ribonucleoside triphosphate phosphatase activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
intracellular anatomical structure	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
extracellular vesicle	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

136 interactions, top by confidence:

A	B	Type	Score
CBX7	BMI1	psi-mi:“MI:0914”(association)	0.940
RAB11A	RAB11FIP3	psi-mi:“MI:0914”(association)	0.860
MED20	MED19	psi-mi:“MI:0914”(association)	0.840
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
ARL4C	RGS12	psi-mi:“MI:0914”(association)	0.640
RAB8A	WDR91	psi-mi:“MI:0914”(association)	0.600
ARF5	ACY3	psi-mi:“MI:0915”(physical association)	0.560
ARF5	DTX3	psi-mi:“MI:0915”(physical association)	0.560
ERBB2	ARF5	psi-mi:“MI:0915”(physical association)	0.550
SNRNP27	UBA6	psi-mi:“MI:0914”(association)	0.530
A4GNT	POTEF	psi-mi:“MI:0914”(association)	0.530
APLNR	METTL15	psi-mi:“MI:0914”(association)	0.530
SLC15A1	METTL15	psi-mi:“MI:0914”(association)	0.530
IL20RA	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
NT5E	SCAMP1	psi-mi:“MI:0914”(association)	0.530
CDH13	INSIG1	psi-mi:“MI:0914”(association)	0.530
ALPI	ALPP	psi-mi:“MI:0914”(association)	0.530
RHOBTB3	ARF5	psi-mi:“MI:0914”(association)	0.530
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530

BioGRID (287): ARF5 (Reconstituted Complex), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS), ARF5 (Affinity Capture-MS)

ESM2 similar proteins: A8ISN6, B5FYQ0, O00909, O45379, O48649, O48920, P0CM16, P0CM17, P0DH91, P18085, P25160, P36397, P36405, P37996, P38116, P40616, P40940, P49076, P49702, P51644, P51821, P56559, P61208, P61211, P61212, P61750, P61751, P84081, P84082, P84083, P84084, P84085, Q06396, Q19705, Q1MTE5, Q20758, Q2TBW6, Q2YDM1, Q3SZF2, Q52NJ4

Diamond homologs: A1CRG9, A1D4D1, A3LTA2, A5DR82, A5E5G3, A8ISN6, O04266, O04267, O04834, O45379, O48649, O48920, P0C583, P0C950, P0C951, P0CM16, P0CM17, P0CR30, P0CR31, P0CT16, P0CT17, P0DH91, P11076, P18085, P19146, P20606, P22274, P34727, P36397, P36536, P36579, P38116, P40940, P40945, P40994, P49702, P51643, P51821, P51823, P51824

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ASAP2	“up-regulates activity”	ARF5	“gtpase-activating protein”
ARF5	up-regulates	Vesicle_transport

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 157 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
COPI-mediated anterograde transport	10	9.6×	5e-05
COPI-dependent Golgi-to-ER retrograde traffic	9	8.8×	3e-04

GO biological processes:

GO term	Partners	Fold	FDR
intra-Golgi vesicle-mediated transport	5	18.3×	4e-03
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	6	14.0×	4e-03
intracellular protein transport	11	5.0×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

25 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	14
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
148342	GRCh38/hg38 7q31.32-32.1(chr7:123829366-127947731)x1	Likely pathogenic

SpliceAI

510 predictions. Top by Δscore:

Variant	Effect	Δscore
7:127589081:A:AG	acceptor_gain	1.0000
7:127589081:AGTT:A	acceptor_gain	1.0000
7:127589082:G:GG	acceptor_gain	1.0000
7:127589082:GTT:G	acceptor_gain	1.0000
7:127589082:GTTG:G	acceptor_gain	1.0000
7:127589163:GGTGA:G	donor_loss	1.0000
7:127589164:G:GA	donor_loss	1.0000
7:127589165:T:A	donor_loss	1.0000
7:127589473:A:AG	acceptor_gain	1.0000
7:127589474:A:G	acceptor_gain	1.0000
7:127589477:A:AG	acceptor_gain	1.0000
7:127589482:CA:C	acceptor_loss	1.0000
7:127589483:A:AG	acceptor_gain	1.0000
7:127589484:G:GT	acceptor_gain	1.0000
7:127589484:GGC:G	acceptor_gain	1.0000
7:127590059:T:A	acceptor_gain	1.0000
7:127590061:CCCA:C	acceptor_loss	1.0000
7:127590063:CA:C	acceptor_loss	1.0000
7:127590064:A:AG	acceptor_gain	1.0000
7:127590064:AG:A	acceptor_gain	1.0000
7:127590064:AGG:A	acceptor_gain	1.0000
7:127590065:G:GG	acceptor_gain	1.0000
7:127590065:GG:G	acceptor_gain	1.0000
7:127590065:GGG:G	acceptor_gain	1.0000
7:127590065:GGGC:G	acceptor_gain	1.0000
7:127590065:GGGCC:G	acceptor_gain	1.0000
7:127590133:AGATG:A	donor_gain	1.0000
7:127590134:GATG:G	donor_gain	1.0000
7:127590134:GATGG:G	donor_gain	1.0000
7:127590135:ATG:A	donor_gain	1.0000

AlphaMissense

1172 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:127589085:G:C	G24R	1.000
7:127589086:G:A	G24D	1.000
7:127589100:G:C	G29R	1.000
7:127589100:G:T	G29C	1.000
7:127589101:G:A	G29D	1.000
7:127589101:G:T	G29V	1.000
7:127589103:A:C	K30Q	1.000
7:127589104:A:T	K30M	1.000
7:127589105:G:C	K30N	1.000
7:127589105:G:T	K30N	1.000
7:127589107:C:T	T31I	1.000
7:127589125:T:C	L37P	1.000
7:127589158:C:T	T48I	1.000
7:127589163:G:C	G50R	1.000
7:127589485:G:A	G50D	1.000
7:127589487:T:A	F51I	1.000
7:127589487:T:C	F51L	1.000
7:127589488:T:C	F51S	1.000
7:127589489:C:A	F51L	1.000
7:127589489:C:G	F51L	1.000
7:127589492:T:A	N52K	1.000
7:127589492:T:G	N52K	1.000
7:127589530:T:A	V65D	1.000
7:127589532:T:A	W66R	1.000
7:127589532:T:C	W66R	1.000
7:127589533:G:C	W66S	1.000
7:127589534:G:C	W66C	1.000
7:127589534:G:T	W66C	1.000
7:127589535:G:C	D67H	1.000
7:127589535:G:T	D67Y	1.000

dbSNP variants (sampled 300 via entrez): RS1000175369 (7:127590330 C>G), RS1000696746 (7:127590392 G>T), RS1000997314 (7:127592035 T>C), RS1001174520 (7:127591967 C>T), RS1001291992 (7:127591448 C>T), RS1001426199 (7:127587445 A>C), RS1002516682 (7:127587065 G>A), RS1003119206 (7:127588301 C>T), RS1003130437 (7:127588423 C>A,T), RS1003540058 (7:127588430 TCCC>T,TCC,TCCCC), RS1004076200 (7:127589344 T>C), RS1004133152 (7:127589648 G>A), RS1005083470 (7:127590737 T>G), RS1005113416 (7:127588169 G>A), RS1005245803 (7:127589866 T>C,G)

Disease associations

OMIM: gene MIM:103188 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001919_1	Type 2 diabetes	2.000000e-10

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5986 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	affects expression	1
arsenite	affects binding, increases reaction	1
tetrabromobisphenol A	decreases expression	1
ochratoxin A	affects binding	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	decreases expression	1
Diethylstilbestrol	decreases expression	1
Dinitrochlorobenzene	affects binding	1
Doxorubicin	decreases expression	1
Gasoline	affects cotreatment, increases abundance, increases expression	1
Ivermectin	decreases expression	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, increases abundance, increases expression	1
Selenium	increases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	affects expression	1
Valproic Acid	increases expression	1
Vitamin E	increases expression	1
Sodium Selenite	increases expression	1
1-Butanol	affects cotreatment, increases abundance, increases expression	1
Particulate Matter	affects cotreatment, increases abundance, increases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4119054	Binding	Binding affinity to ARF5 in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2RZ	Abcam HEK293T ARF5 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.